SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Phil Cressman who wrote (2571)2/9/2000 1:10:00 PM
From: Walter Morton  Read Replies (1) | Respond to of 2742
 
With that latest patent news that I posted a few days ago, CIST may have made serious progress in their relationship with Pasteur Meriux Connaught, a subsidiary of Aventis (NYSE:AVE)(formerly known as Rhone-Pouleno Group (NYSE: RP)).

Further, this new patent must be worth a lot more than $20 million.



To: Phil Cressman who wrote (2571)2/18/2000 11:59:00 AM
From: Walter Morton  Respond to of 2742
 
Did PMC exercise its warrants for 666,667 shares yesterday?

PMC has a new name. Aventis Pasteur operated under the Pasteur Merieux Connaught name until the creation of Aventis.

Aventis was launched on December 15, 1999 through the merger of Hoechst AG and Rhone-Poulenc SA.
Aventis Pasteur is the human vaccines business of Aventis S.A. (NYSE:AVE): quote.yahoo.com


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News